Europe - Euronext Brussels - EBR:UCB - BE0003739530 - Common Stock
UCB gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 55 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of UCB get a neutral evaluation. Nothing too spectacular is happening here. UCB shows excellent growth, but is valued quite expensive already. These ratings would make UCB suitable for growth investing!
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.75% | ||
| ROE | 13.76% | ||
| ROIC | 11.63% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.58% | ||
| PM (TTM) | 19.45% | ||
| GM | 73.38% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 2.43 | ||
| Altman-Z | 5.47 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.35 | ||
| Quick Ratio | 1.01 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.81 | ||
| Fwd PE | 25.48 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 43.01 | ||
| EV/EBITDA | 20.7 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.38% |
ChartMill assigns a fundamental rating of 6 / 10 to UCB.BR.
ChartMill assigns a valuation rating of 3 / 10 to UCB SA (UCB.BR). This can be considered as Overvalued.
UCB SA (UCB.BR) has a profitability rating of 6 / 10.
The Price/Earnings (PE) ratio for UCB SA (UCB.BR) is 40.81 and the Price/Book (PB) ratio is 5.26.
The Earnings per Share (EPS) of UCB SA (UCB.BR) is expected to grow by 60.25% in the next year.